These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
☒
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
|
|
☐
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
|
|
Nevada
|
|
45-2859440
|
|
(State
or other jurisdiction of incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
|
Large
accelerated filer ☐
|
Accelerated
filer ☐
|
Non-accelerated
filer ☐
|
Smaller
reporting company ☒
|
|
|
|
(Do not
check if a smaller
Reporting
company)
|
|
|
|
|
PAGE
|
|
|
|
|
|
|
PART I - FINANCIAL INFORMATION
|
|
|
|
|
|
|
Item
1.
|
Financial
Statements
|
3
|
|
|
|
|
|
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
30
|
|
|
|
|
|
Item
3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
38
|
|
|
|
|
|
Item
4.
|
Controls
and Procedures
|
38
|
|
|
|
|
|
|
PART II - OTHER INFORMATION
|
|
|
|
|
|
|
Item
1.
|
Legal
Proceedings
|
39
|
|
|
|
|
|
Item
1A.
|
Risk
Factors
|
39
|
|
|
|
|
|
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
39
|
|
|
|
|
|
Item
3.
|
Defaults
Upon Senior Securities
|
40
|
|
|
|
|
|
Item
4.
|
Mine
Safety Disclosures
|
40
|
|
|
|
|
|
Item
5.
|
Other
Information
|
40
|
|
|
|
|
|
Item
6.
|
Exhibits
|
43
|
|
|
|
|
|
|
SIGNATURES
|
45
|
|
|
|
PAGE
|
|
|
|
|
|
Condensed
Consolidated Balance Sheets as of September 30, 2016 and December
31, 2015 (unaudited)
|
|
4
|
|
|
|
|
|
Condensed
Consolidated Statements of Operations for the three and nine months
ended September 30, 2016 and September 30, 2015
(unaudited)
|
|
5
|
|
|
|
|
|
Condensed
Consolidated Statements of Comprehensive Loss for the three and
nine months ended September 30, 2016 and September 30, 2015
(unaudited)
|
|
6
|
|
|
|
|
|
Condensed
Consolidated Statements of Cash Flows for the nine months ended
September 30, 2016 and September 30, 2015 (unaudited)
|
|
7
|
|
|
|
|
|
Notes
to Condensed Consolidated Financial Statements
(unaudited)
|
|
8
|
|
|
September
30,
|
December
31,
|
|
|
2016
|
2015
|
|
ASSETS
|
|
|
|
Current
assets
|
|
|
|
Cash
|
$
7,724
|
$
553,696
|
|
Accounts
receivable, less allowance for doubtful accounts of $-0- and
$39,847 respectively
|
44,404
|
64,639
|
|
Prepaid expenses
and other current assets
|
45,970
|
42,553
|
|
Total current
assets
|
98,098
|
660,888
|
|
|
|
|
|
Property and
equipment, at cost, less accumulated depreciation
|
17,398
|
15,108
|
|
Investments in
associated companies
|
1,166
|
1,134
|
|
Intangible assets,
net
|
-
|
785,070
|
|
Total
assets
|
$
116,662
|
$
1,462,200
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' (DEFICIENCY) EQUITY
|
|
|
|
Current
liabilities
|
|
|
|
Line of
credit
|
$
55,479
|
$
-
|
|
Accounts
payable
|
101,280
|
88,774
|
|
Accrued expenses
and other current liabilities
|
262,486
|
301,896
|
|
Current maturities
of notes payable
|
33,916
|
32,993
|
|
Subordinated loan
– related party
|
75,059
|
73,016
|
|
Total current
liabilities
|
528,220
|
496,679
|
|
|
|
|
|
Notes payable, less
current maturities
|
33,902
|
49,476
|
|
8% Convertible
promissory notes payable, net of $1,126,807 and $722,622 discount,
respectively
|
733,193
|
587,378
|
|
Total
liabilities
|
1,295,315
|
1,133,533
|
|
|
|
|
|
Commitments
|
|
|
|
|
|
|
|
Stockholders'
(Deficiency) Equity
|
|
|
|
|
|
|
|
Preferred
stock
|
|
|
|
Authorized:
$0.001 par value, 10,000,000 shares authorized
|
-
|
-
|
|
Issued
and outstanding: nil preferred shares
|
|
|
|
Common
stock
|
|
|
|
Authorized:
$0.001 par value, 290,000,000 shares authorized
|
|
|
|
Issued
and outstanding: 37,277,039 and 36,909,472,
respectively
|
37,277
|
36,909
|
|
|
|
|
|
Additional paid-in
capital
|
8,302,256
|
7,635,104
|
|
Accumulated other
comprehensive loss
|
(297,000
)
|
(322,183
)
|
|
Accumulated
deficit
|
(9,142,389
)
|
(6,994,274
)
|
|
Total Symbid Corp.
stockholders' (deficiency) equity
|
(1,099,856
)
|
355,556
|
|
Noncontrolling
interests
|
(78,797
)
|
(26,889
)
|
|
Total stockholders'
(deficiency) equity
|
(1,178,653
)
|
328,667
|
|
Total liabilities
and stockholders' equity
|
$
116,662
|
$
1,462,200
|
|
|
Three months
ended
September
30,
|
Nine months
ended
September
30,
|
||
|
|
2016
|
2015
|
2016
|
2015
|
|
Revenues
|
|
|
|
|
|
Crowdfunding
|
$
51,748
|
$
58,979
|
$
181,389
|
$
191,177
|
|
The Funding
Network
|
(3,155
)
|
-
|
11,143
|
-
|
|
Other
|
(2,680
)
|
9,787
|
631
|
43,825
|
|
Total
revenues
|
45,913
|
68,766
|
193,163
|
235,002
|
|
Operating
expenses
|
|
|
|
|
|
Selling, general
and administrative
|
103,243
|
359,779
|
1,019,277
|
1,188,655
|
|
Professional
fees
|
7,853
|
226,533
|
275,441
|
565,996
|
|
Research and
development costs
|
1,674
|
5,091
|
28,332
|
53,410
|
|
Depreciation and
amortization
|
1,360
|
36,414
|
75,939
|
109,554
|
|
Bad debt expense
(recoveries)
|
(13,170
)
|
4,121
|
(42,907
)
|
14,013
|
|
Impairment
expense
|
-
|
-
|
740,073
|
-
|
|
Total operating
expenses
|
100,960
|
631,938
|
2,096,155
|
1,931,628
|
|
|
|
|
|
|
|
Operating
loss
|
(55,047
)
|
(563,172
)
|
(1,902,992
)
|
(1,696,626
)
|
|
|
|
|
|
|
|
Other
income (expense)
|
|
|
|
|
|
Interest expense
and amortization of debt discount
|
(91,470
)
|
(69,121
)
|
(246,641
)
|
(74,401
)
|
|
Other
income
|
-
|
-
|
351
|
11,504
|
|
Other
expense
|
-
|
-
|
(2,986
)
|
(7,791
)
|
|
Total other
expense
|
(91,470
)
|
(69,121
)
|
(249,276
)
|
(70,688
)
|
|
|
|
|
|
|
|
Net
loss
|
(146,517
)
|
(632,293
)
|
(2,152,268
)
|
(1,767,314
)
|
|
|
|
|
|
|
|
Net income (loss)
attributable to noncontrolling interests
|
9,787
|
(27,477
)
|
(4,153
)
|
(58,480
)
|
|
|
|
|
|
|
|
Net
loss attributable to Symbid Corp. stockholders
|
$
(156,304
)
|
$
(604,816
)
|
$
(2,148,115
)
|
$
(1,708,834
)
|
|
|
|
|
|
|
|
Basic and diluted
net loss per common share
|
$
(0.00
)
|
$
(0.02
)
|
$
(0.06
)
|
$
(0.05
)
|
|
|
|
|
|
|
|
Weighted average
number of shares outstanding
|
|
|
|
|
|
Basic and
diluted
|
37,277,039
|
34,924,982
|
37,102,646
|
34,707,412
|
|
|
|
|
|
|
|
Share-based
compensation expense included in operating expenses:
|
|
|
|
|
|
Selling, general
and administrative
|
$
(14,391
)
|
$
20,424
|
$
33,187
|
$
238,861
|
|
Research and
development costs
|
-
|
910
|
(942
)
|
32,849
|
|
|
$
(14,391
)
|
$
21,334
|
$
32,245
|
$
271,710
|
|
|
Three months
ended
September
30,
|
Nine months
ended
September
30,
|
||
|
|
2016
|
2015
|
2016
|
2015
|
|
|
|
|
|
|
|
Net
loss
|
$
(146,517
)
|
$
(632,293
)
|
$
(2,152,268
)
|
$
(1,767,314
)
|
|
Other comprehensive
loss:
|
|
|
|
|
|
Foreign currency
translation income (loss)
|
(1,646
)
|
(9,918
)
|
25,183
|
(99,563
)
|
|
Comprehensive
loss
|
(148,163
)
|
(642,211
)
|
(2,127,085
)
|
(1,866,877
)
|
|
|
|
|
|
|
|
Net income (loss)
attributable to noncontrolling interests
|
9,787
|
(27,477
)
|
(4,153
)
|
(58,480
)
|
|
Foreign currency
translation income (loss) attributable to noncontrolling
interests
|
(18
)
|
264
|
(1,584
)
|
10,396
|
|
Comprehensive
income (loss) attributable to noncontrolling interests
|
9,769
|
(27,213
)
|
(5,737
)
|
(48,084
)
|
|
Comprehensive loss
attributable to
Symbid Corp.
stockholders
|
$
(157,932
)
|
$
(614,998
)
|
$
(2,121,348
)
|
$
(1,818,793
)
|
|
|
Nine months
ended
September
30,
|
|
|
|
2016
|
2015
|
|
Cash
flows from operating activities
|
|
|
|
Net
loss
|
$
(2,152,268
)
|
$
(1,767,314
)
|
|
Adjustments to
reconcile net loss to net cash
|
|
|
|
used in operating
activities
|
|
|
|
Employee and
non-employee share based compensation
|
32,245
|
271,710
|
|
Shares issued under
service agreements
|
-
|
182,386
|
|
Depreciation and
amortization
|
75,939
|
109,554
|
|
Amortization of
debt discount
|
145,815
|
58,132
|
|
Impairment of
intangible asset
|
740,073
|
-
|
|
Warrant liability -
fair value adjustment
|
-
|
7,791
|
|
Provision for
doubtful accounts
|
(40,772
)
|
14,013
|
|
Loss on liquidation
of Symbid Italia
|
2,986
|
-
|
|
Gain on sale of
investment in Gambitious B.V.
|
-
|
(11,504
)
|
|
Changes
in assets and liabilities
|
|
|
|
Accounts
receivable
|
62,711
|
(5,422
)
|
|
Prepaid expenses
and other current assets
|
11,570
|
(14,196
)
|
|
Accounts
payable
|
10,862
|
(231,750
)
|
|
Accrued expenses
and other current liabilities
|
22,371
|
(71,882
)
|
|
Net cash used in
operating activities
|
(1,088,468
)
|
(1,458,482
)
|
|
|
|
|
|
Cash
flows from investing activities
|
|
|
|
Proceeds from sale
of associated companies
|
$
-
|
$
20,309
|
|
Net payment from
liquidation of Symbid Italia
|
(44,744
)
|
-
|
|
Acquisition of
property and equipment
|
(5,784
)
|
-
|
|
Net cash (used in)
provided by investing activities
|
(50,528
)
|
20,309
|
|
|
|
|
|
Cash
flows from financing activities
|
|
|
|
Line of credit,
net
|
$
55,221
|
$
-
|
|
Repayments of notes
payable
|
(16,879
)
|
(16,872
)
|
|
Proceeds from
convertible notes
|
550,000
|
1,500,000
|
|
Proceeds from the
issuance of common stock, net of issuance costs
|
-
|
724,116
|
|
Net cash provided
by financing activities
|
588,342
|
2,207,244
|
|
|
|
|
|
Effect of exchange
rate changes on cash
|
4,682
|
(41,294
)
|
|
Net
(decrease) / increase in cash
|
(545,972
)
|
727,777
|
|
|
|
|
|
Cash and cash
equivalents, beginning of period
|
553,696
|
233,068
|
|
Cash
and cash equivalents, end of period
|
$
7,724
|
$
960,845
|
|
|
|
|
|
Supplemental
cash flow disclosures
|
|
|
|
Interest
paid
|
$
3,847
|
$
9,145
|
|
|
|
|
|
Non-cash
investing and financing activities
|
|
|
|
Change in accrued
expenses related to non-employee share based payments
|
$
85,275
|
$
13,080
|
|
Deconsolidation of
Symbid Italia assets
|
5,901
|
-
|
|
Beneficial
conversion feature
|
550,000
|
-
|
|
Conversion of 8%
convertible promissory notes
|
-
|
190,000
|
|
Reallocation of
noncontrolling interests
|
-
|
129,918
|
|
●
|
Limited
or no structured distribution channels for SME finance other than
banks, increasing the mismatch between entrepreneurs and
financiers;
|
|
●
|
No
centralized platform for (alternative) financiers, making it
difficult and inefficient to find the right financier at the right
time;
|
|
●
|
No
standardized data protocols for SME data, leading to costly and
time-intensive (offline) screening and monitoring;
|
|
●
|
Limited
financial skills of entrepreneurs leading to unnecessary
inefficiencies and obstacles within the financing process;
and
|
|
●
|
Decline
in bank financing due to new regulations and recent financial
crises, leaving a vacuum in the life cycle of SME
financing.
|
|
|
September
30,
2016
|
December
31,
2015
|
|
Current
assets
|
$
45,593
|
$
73,600
|
|
Current
liabilities
|
$
125,180
|
$
186,214
|
|
|
September
30,
|
December
31,
|
|
|
2016
|
2015
|
|
Software
|
$
1,019,103
|
$
984,267
|
|
Less - Accumulated
amortization
|
(274,394
)
|
(199,197
)
|
|
Impairment
|
(740,063
)
|
-
|
|
Translation
adjustment
|
(4,646
)
|
-
|
|
|
$
-
|
$
785,070
|
|
|
September
30,
2016
|
December
31,
2015
|
|
Advisory
costs
|
$
31,984
|
$
89,829
|
|
Interest
|
141,611
|
45,863
|
|
Wage tax
return
|
2,005
|
19,035
|
|
Holiday pay
allowance/Net salary
|
13,133
|
24,533
|
|
Penalty
waiver
|
14,630
|
14,630
|
|
Marketing
|
24,804
|
38,069
|
|
Accrued stock
liability
|
11,018
|
20,541
|
|
Other current
liabilities
|
20,787
|
49,396
|
|
|
$
262,486
|
$
301,896
|
|
|
|
|
|
|
September
30,
|
December
31,
|
|
|
2016
|
2015
|
|
Line of
credit
|
$
55,479
|
$
-
|
|
Working capital
facility
|
67,818
|
82,469
|
|
Subordinated loan
– related party
|
75,059
|
73,016
|
|
8% Convertible
promissory notes
|
733,193
|
587,378
|
|
Total notes
payable
|
931,549
|
742,863
|
|
Less - Current
Maturities
|
(164,454
)
|
(106,009
)
|
|
Notes
payable, less current maturities
|
$
767,095
|
$
636,854
|
|
|
Principal
|
Unamortized
Debt
Discount
|
Balance as of
September
30,
2016
|
|
8% Convertible
promissory notes July 14, 2015
|
$
60,000
|
$
(9,458
)
|
$
50,542
|
|
8% Convertible
promissory notes September 8, 2015
|
1,250,000
|
(567,350
)
|
682,650
|
|
8% Convertible
promissory notes June 1, 2016
|
550,000
|
(549,999
)
|
1
|
|
|
$
1,860,000
|
$
(1,126,807
)
|
$
733,193
|
|
|
Three months
ended September 30, 2016
|
Nine months
ended September 30, 2016
|
|
|
|
|
|
Cash Interest
Expense
|
$
39,096
|
$
100,826
|
|
Coupon
interest expense
|
|
|
|
Noncash Interest
Expense
|
|
|
|
Amortization
of debt discount
|
52,374
|
145,815
|
|
|
$
91,470
|
$
246,641
|
|
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
||
|
|
2016
|
2015
|
2016
|
2015
|
|
Symbid Coop-
100%
|
$
9,787
|
$
(14,149
)
|
$
35,992
|
$
(24,371
)
|
|
Symbid Italia
– 49.9%
|
-
|
(13,328
)
|
(40,145
)
|
(34,109
)
|
|
Total
|
$
9,787
|
$
(27,477
)
|
$
(4,153
)
|
$
(58,480
)
|
|
|
September
30,
2016
|
December
31, 2015 |
|
Symbid Coop -
100%
|
$
(78,797
)
|
$
(112,614
)
|
|
Symbid Italia
– 49.9%
|
-
|
85,725
|
|
Total
deficiency attributable to noncontrolling interests
|
$
(78,797
)
|
$
(26,889
)
|
|
For
the years ended
December 31,
|
Shares of
Restricted
Common
Stock
|
|
2016
|
500,000
|
|
2017
|
250,000
|
|
|
750,000
|
|
|
Three months
ended
September
30,
|
Nine months
ended
September
30,
|
||
|
|
2016
|
2015
|
2016
|
2015
|
|
Revenues
|
|
|
|
|
|
Crowdfunding
|
$
51,748
|
$
58,979
|
$
181,389
|
$
191,177
|
|
The Funding
Network
|
(3,155
)
|
-
|
11,143
|
-
|
|
Other
|
(2,680
)
|
9,787
|
631
|
43,825
|
|
Total
revenues
|
45,913
|
68,766
|
193,163
|
235,002
|
|
Operating
expenses
|
|
|
|
|
|
Selling, general
and administrative
|
103,243
|
359,779
|
1,019,277
|
1,188,655
|
|
Professional
fees
|
7,853
|
226,533
|
275,441
|
565,996
|
|
Research and
development costs
|
1,674
|
5,091
|
28,332
|
53,410
|
|
Depreciation and
amortization
|
1,360
|
36,414
|
75,939
|
109,554
|
|
Bad debt expense
(recoveries)
|
(13,170
)
|
4,121
|
(42,907
)
|
14,013
|
|
Impairment
expense
|
-
|
-
|
740,073
|
-
|
|
Total operating
expenses
|
100,960
|
631,938
|
2,096,155
|
1,931,628
|
|
|
|
|
|
|
|
Operating
loss
|
(55,047
)
|
(563,172
)
|
(1,902,992
)
|
(1,696,626
)
|
|
|
|
|
|
|
|
Other
income (expense)
|
|
|
|
|
|
Interest expense
and amortization of debt discount
|
(91,470
)
|
(69,121
)
|
(246,641
)
|
(74,401
)
|
|
Other
income
|
-
|
-
|
351
|
11,504
|
|
Other
expense
|
-
|
-
|
(2,986
)
|
(7,791
)
|
|
Total other
expense
|
(91,470
)
|
(69,121
)
|
(249,276
)
|
(70,688
)
|
|
|
|
|
|
|
|
Net
loss
|
(146,517
)
|
(632,293
)
|
(2,152,268
)
|
(1,767,314
)
|
|
|
|
|
|
|
|
Net income (loss)
attributable to noncontrolling interests
|
9,787
|
(27,477
)
|
(4,153
)
|
(58,480
)
|
|
|
|
|
|
|
|
Net
loss attributable to Symbid Corp. stockholders
|
$
(156,304
)
|
$
(604,816
)
|
$
(2,148,115
)
|
$
(1,708,834
)
|
|
|
|
|
|
|
|
Basic and diluted
net loss per common share
|
$
(0.00
)
|
$
(0.02
)
|
$
(0.06
)
|
$
(0.05
)
|
|
|
|
|
|
|
|
Weighted average
number of shares outstanding
|
|
|
|
|
|
Basic and
diluted
|
37,277,039
|
34,924,982
|
37,102,646
|
34,707,412
|
|
Exhibit
Number
|
|
Description of
Exhibit
|
|
10.1
|
|
Form of
November 15, 2016 Note Termination and Conversion Agreement (2016
Notes)
|
|
10.2
|
|
Form of
November 15, 2016 Note Termination and Conversion Agreement (2015
Notes)
|
|
10.3
|
|
Right
of First Refusal Agreement dated November 15, 2016
|
|
10.4
|
|
Intellectual
Property License Termination Agreement dated November 15, 2016
between Symbid B.V. and Symbid Coöperatie U.A.
|
|
10.5
|
|
Addendum
2 dated November 15, 2016 to October 16, 2013 Intellectual Property
License and Transfer Agreement between Stichting Symbid IP
Foundation and Symbid Holding B.V.
|
|
10.6
|
|
Intellectual
Property License and Transfer Agreement dated November 15, 2016
between Symbid Coöperatie U.A. and Stichting Symbid IP
Foundation
|
|
10.7
|
|
Securities
Purchase Agreement dated as of December 9,2016 between Registrant
and CKR Law LLP.
|
|
31.1
|
|
Certification
of Principal Executive Officer Pursuant to Rule 13a-14
|
|
31.2
|
|
Certification
of Principal Financial Officer Pursuant to Rule 13a-14
|
|
32.1**
|
|
CEO
Certification Pursuant to Section 906 of the Sarbanes-Oxley
Act
|
|
32.2**
|
|
CFO
Certification Pursuant to Section 906 of the Sarbanes-Oxley
Act
|
|
101.INS
|
|
XBRL
Instance Document
|
|
101.SCH
|
|
XBRL
Taxonomy Extension Schema Document
|
|
101.CAL
|
|
XBRL
Taxonomy Extension Calculation Linkbase Document
|
|
101.LAB
|
|
XBRL
Taxonomy Extension Labels Linkbase Document
|
|
101.PRE
|
|
XBRL
Taxonomy Extension Presentation Linkbase Document
|
|
101.DEF
|
|
XBRL
Taxonomy Extension Definition Linkbase Document
|
|
|
SYMBID
CORP.
|
|
|
|
|
|
|
December
14, 2016
|
By:
|
/s/ Korstiaan Zandvliet
|
|
|
Korstiaan
Zandvliet, Chief Executive Officer
|
|
|
|
|
|
|
|
SYMBID
CORP.
|
|
|
|
|
|
|
December
14, 2016
|
By:
|
/s/ Maarten van der Sanden
|
|
|
Maarten van der
Sanden, Chief Financial Officer
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|